Evidence map›Paper›PMID 38096736›Full record

ArticleBiologicals : journal of the International Association of Biological Standardization2024

An antibody-free evaluation of an mRNA COVID-19 vaccine.

Paul J Branham, Hans C Cooper, Yulanda M Williamson, Fabio N Najjar, William J H Sutton, Carrie L Pierce-Ruiz, John R Barr, Tracie L Williams

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biologicals : journal of the International Association of Biological Standardization, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Paul J BranhamOak Ridge Institute for Science and Education, Centers for Disease Control and Prevention, Atlanta, GA, 30341, USA.
Hans C CooperNational Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA, 30341, USA.
Yulanda M WilliamsonNational Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA, 30341, USA.
Fabio N NajjarOak Ridge Institute for Science and Education, Centers for Disease Control and Prevention, Atlanta, GA, 30341, USA.
William J H SuttonOak Ridge Institute for Science and Education, Centers for Disease Control and Prevention, Atlanta, GA, 30341, USA.
Carrie L Pierce-RuizNational Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA, 30341, USA.
John R BarrNational Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA, 30341, USA.
Tracie L WilliamsNational Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA, 30341, USA. Electronic address: tracie.williams@cdc.hhs.gov.
Centers for Disease Control and Prevention · US

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

This manuscript describes the use of an analytical assay that combines transfection of mammalian cells and isotope dilution mass spectrometry (IDMS) for accurate quantification of antigen expression. Expired mRNA COVID-19 vaccine material was stored at 4 °C, room temperature (∼25 °C), and 56 °C over a period of 5 weeks. The same vaccine was also exposed to 5 freeze-thaw cycles. Every week, the spike protein antigenic expression in mammalian (BHK-21) cells was evaluated. Housekeeping proteins, β-actin and GAPDH, were simultaneously quantified to account for the variation in cell counts that occurs during maintenance and growth of cell cultures. Data show that vaccine stored at elevated temperatures results in reduced spike protein expression. Also, maintaining the vaccine in ultracold conditions or exposing the vaccine to freeze-thaw cycles had less effect on the vaccine's ability to produce the antigen in mammalian cells. We describe the use of IDMS as an antibody-free means to accurately quantify expressed protein from mammalian cells transfected with mRNA vaccine.

Indexed as

COVID-19COVID-19 VaccinesAnimalsFreezingHumansMammalsRNA, MessengerSpike Glycoprotein, CoronavirusCOVID-19 VaccinesRNA, MessengerSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Identifiers

PMID38096736
PMCPMC10961194
OpenAlexW4389703781

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.